1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Brain Cancer - Pipeline Review, H1 2015

Brain Cancer - Pipeline Review, H1 2015

  • January 2015
  • -
  • Global Markets Direct
  • -
  • 263 pages

Brain Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Brain Cancer - Pipeline Review, H1 2015’, provides an overview of the Brain Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Brain Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Brain Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Brain Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Brain Cancer - Pipeline Review, H1 2015
Table of Contents
Table of Contents 2
Introduction 8
Global Markets Direct Report Coverage 8
Brain Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Brain Cancer - Overview 10
Pipeline Products for Brain Cancer - Comparative Analysis 11
Brain Cancer - Therapeutics under Development by Companies 12
Brain Cancer - Therapeutics under Investigation by Universities/Institutes 16
Brain Cancer - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Brain Cancer - Products under Development by Companies 20
Brain Cancer - Products under Investigation by Universities/Institutes 24
Brain Cancer - Companies Involved in Therapeutics Development 25
AbbVie Inc. 25
AngioChem Inc. 26
Arrien Pharmaceuticals, LLC 27
BBB Therapeutics B.V. 28
biOasis Technologies Inc. 29
Bionomics Limited 30
Bristol-Myers Squibb Company 31
Cavion LLC 32
Critical Outcome Technologies Inc. 33
CureFAKtor Pharmaceuticals, LLC 34
Diffusion Pharmaceuticals LLC 35
e-Therapeutics plc 36
Eisai Co., Ltd. 37
Exelixis, Inc. 38
GlaxoSmithKline plc 39
Hutchison MediPharma Limited 40
Merrimack Pharmaceuticals, Inc. 41
Nanobiotix 42
Nektar Therapeutics 43
Nerviano Medical Sciences S.r.l. 44
Neuralstem, Inc. 45
Novartis AG 46
Oncology Research International Limited 47
Pfizer Inc. 48
Philogen S.p.A. 49
Phosplatin Therapeutics 50
Prana Biotechnology Limited 51
Puma Biotechnology, Inc. 52
RadioRx, Inc. 53
Sagetis Biotech, S.L. 54
Sanofi 55
Spectrum Pharmaceuticals, Inc. 56
Stemline Therapeutics, Inc. 57
Takeda Pharmaceutical Company Limited 58
ThromboGenics NV 59
Tocagen Inc. 60
Zymeworks Inc. 61
Brain Cancer - Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Combination Products 63
Assessment by Target 64
Assessment by Mechanism of Action 67
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 74
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 74
2B3-101 - Drug Profile 76
ANG-1005 - Drug Profile 78
ANG-4043 - Drug Profile 80
ARN-7016 - Drug Profile 81
BNC-105 - Drug Profile 82
BT-2111 - Drug Profile 83
cabazitaxel - Drug Profile 84
cabozantinib s-malate - Drug Profile 86
CFAKC-4 - Drug Profile 89
COTI-2 - Drug Profile 90
dabrafenib mesylate - Drug Profile 93
dacomitinib - Drug Profile 96
dexanabinol - Drug Profile 98
Drug for Brain Metastasis - Drug Profile 100
erismodegib - Drug Profile 101
etirinotecan pegol - Drug Profile 104
Gene Therapy for Brain Cancer - Drug Profile 107
Gene Therapy to Activate p53 for Oncology - Drug Profile 108
HMPL-813 - Drug Profile 109
ipilimumab - Drug Profile 110
irinotecan sucrosofate liposomal - Drug Profile 113
KML-001 - Drug Profile 116
lapatinib ditosylate - Drug Profile 118
LEQ-506 - Drug Profile 122
lucanthone hydrochloride - Drug Profile 123
MDNA-55 - Drug Profile 125
mibefradil dihydrochloride - Drug Profile 126
Monoclonal Antibody for Brain Cancer and Metastatic Breast Cancer - Drug Profile 128
NBTX-IV - Drug Profile 129
neratinib - Drug Profile 130
nimotuzumab - Drug Profile 134
NMSE-973 - Drug Profile 137
NSI-566 - Drug Profile 138
ORIL-007 - Drug Profile 140
PB-357 - Drug Profile 141
PBT-519 - Drug Profile 142
pritumumab - Drug Profile 143
PT-112 - Drug Profile 145
RAD-1901 - Drug Profile 146
radretumab - Drug Profile 148
RRX-001 - Drug Profile 150
SAG-002 - Drug Profile 151
SAG-003 - Drug Profile 152
siomycin A - Drug Profile 153
SL-301 - Drug Profile 154
SL-302 - Drug Profile 155
Small Molecule for Brain Cancer - Drug Profile 156
Small Molecule for Brain Cancer and Malignant Glioma - Drug Profile 157
Small Molecule for Oncology - Drug Profile 158
Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma - Drug Profile 159
TB-403 - Drug Profile 160
TBX-02 - Drug Profile 162
TPI-287 - Drug Profile 163
transcrocetinate sodium - Drug Profile 165
TTL-1177 - Drug Profile 166
ubidecarenone - Drug Profile 167
Vaccine for Glioblastoma Multiforme - Drug Profile 169
veliparib - Drug Profile 170
vocimagene amiretrorepvec + flucytosine ER - Drug Profile 173
Brain Cancer - Recent Pipeline Updates 175
Brain Cancer - Dormant Projects 244
Brain Cancer - Discontinued Products 248
Brain Cancer - Product Development Milestones 249
Featured News and Press Releases 249
Appendix 258
Methodology 258
Coverage 258
Secondary Research 258
Primary Research 258
Expert Panel Validation 258
Contact Us 259
Disclaimer 259

List of Tables

Number of Products under Development for Brain Cancer, H1 2015 14
Number of Products under Development for Brain Cancer - Comparative Analysis, H1 2015 15
Number of Products under Development by Companies, H1 2015 17
Number of Products under Development by Companies, H1 2015 (Contd..1) 18
Number of Products under Development by Companies, H1 2015 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2015 20
Comparative Analysis by Late Stage Development, H1 2015 21
Comparative Analysis by Clinical Stage Development, H1 2015 22
Comparative Analysis by Early Stage Development, H1 2015 23
Products under Development by Companies, H1 2015 24
Products under Development by Companies, H1 2015 (Contd..1) 25
Products under Development by Companies, H1 2015 (Contd..2) 26
Products under Development by Companies, H1 2015 (Contd..3) 27
Products under Investigation by Universities/Institutes, H1 2015 28
Brain Cancer - Pipeline by AbbVie Inc., H1 2015 29
Brain Cancer - Pipeline by AngioChem Inc., H1 2015 30
Brain Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 31
Brain Cancer - Pipeline by BBB Therapeutics B.V., H1 2015 32
Brain Cancer - Pipeline by biOasis Technologies Inc., H1 2015 33
Brain Cancer - Pipeline by Bionomics Limited, H1 2015 34
Brain Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015 35
Brain Cancer - Pipeline by Cavion LLC, H1 2015 36
Brain Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2015 37
Brain Cancer - Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015 38
Brain Cancer - Pipeline by Diffusion Pharmaceuticals LLC, H1 2015 39
Brain Cancer - Pipeline by e-Therapeutics plc, H1 2015 40
Brain Cancer - Pipeline by Eisai Co., Ltd., H1 2015 41
Brain Cancer - Pipeline by Exelixis, Inc., H1 2015 42
Brain Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 43
Brain Cancer - Pipeline by Hutchison MediPharma Limited, H1 2015 44
Brain Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 45
Brain Cancer - Pipeline by Nanobiotix, H1 2015 46
Brain Cancer - Pipeline by Nektar Therapeutics, H1 2015 47
Brain Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 48
Brain Cancer - Pipeline by Neuralstem, Inc., H1 2015 49
Brain Cancer - Pipeline by Novartis AG, H1 2015 50
Brain Cancer - Pipeline by Oncology Research International Limited, H1 2015 51
Brain Cancer - Pipeline by Pfizer Inc., H1 2015 52
Brain Cancer - Pipeline by Philogen S.p.A., H1 2015 53
Brain Cancer - Pipeline by Phosplatin Therapeutics, H1 2015 54
Brain Cancer - Pipeline by Prana Biotechnology Limited, H1 2015 55
Brain Cancer - Pipeline by Puma Biotechnology, Inc., H1 2015 56
Brain Cancer - Pipeline by RadioRx, Inc., H1 2015 57
Brain Cancer - Pipeline by Sagetis Biotech, S.L., H1 2015 58
Brain Cancer - Pipeline by Sanofi, H1 2015 59
Brain Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 60
Brain Cancer - Pipeline by Stemline Therapeutics, Inc., H1 2015 61
Brain Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 62
Brain Cancer - Pipeline by ThromboGenics NV, H1 2015 63
Brain Cancer - Pipeline by Tocagen Inc., H1 2015 64
Brain Cancer - Pipeline by Zymeworks Inc., H1 2015 65
Assessment by Monotherapy Products, H1 2015 66
Assessment by Combination Products, H1 2015 67
Number of Products by Stage and Target, H1 2015 69
Number of Products by Stage and Mechanism of Action, H1 2015 72
Number of Products by Stage and Route of Administration, H1 2015 75
Number of Products by Stage and Molecule Type, H1 2015 77
Brain Cancer Therapeutics - Recent Pipeline Updates, H1 2015 179
Brain Cancer - Dormant Projects, H1 2015 248
Brain Cancer - Dormant Projects (Contd..1), H1 2015 249
Brain Cancer - Dormant Projects (Contd..2), H1 2015 250
Brain Cancer - Dormant Projects (Contd..3), H1 2015 251
Brain Cancer - Discontinued Products, H1 2015 252

List of Figures

Number of Products under Development for Brain Cancer, H1 2015 14
Number of Products under Development for Brain Cancer - Comparative Analysis, H1 2015 15
Number of Products under Development by Companies, H1 2015 16
Number of Products under Investigation by Universities/Institutes, H1 2015 20
Comparative Analysis by Clinical Stage Development, H1 2015 22
Comparative Analysis by Early Stage Products, H1 2015 23
Assessment by Monotherapy Products, H1 2015 66
Assessment by Combination Products, H1 2015 67
Number of Products by Top 10 Targets, H1 2015 68
Number of Products by Stage and Top 10 Targets, H1 2015 68
Number of Products by Top 10 Mechanism of Actions, H1 2015 71
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 71
Number of Products by Top 10 Routes of Administration, H1 2015 74
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 75
Number of Products by Top 10 Molecule Types, H1 2015 76
Number of Products by Stage and Top 10 Molecule Types, H1 2015 77

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Brain Cancer: Analytical Tool

Brain Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Glioblastoma Multiforme-Market Insights, Epidemiology and Market Forecast-2023

Glioblastoma Multiforme-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Glioblastoma Multiforme - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • December 2016
    112 pages
  • Cancer  

  • United States  

    North America  

View report >

Cancer Statistics in the US

  • November 2016
    74 pages
  • Cancer  

  • United States  

View report >

Cancer Statistics and Therapy Market in the US - Forecast

  • November 2016
    52 pages
  • Cancer  

    Therapy  

  • United States  

View report >

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.